Mr. Bloom's practice is focused on the representation of emerging and public life science companies, and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic commercial transactions.
Mr. Bloom’s representative clients include, among others: Akero Therapeutics; Alkermes; Alnylam Pharmaceuticals; Aptinyx; Atlas Venture; BeiGene; Black Diamond Therapeutics; BridgeBio; Cabaletta; Casma Therapeutics; Centessa Pharmaceuticals; Compass Pathways; Coridea; Cullinan Oncology; ElevateBio; Esperion Therapeutics; Eventide; Faze Medicines; Fusion Pharmaceuticals; Gate Therapeutics; Gemini Therapeutics; Global Blood Therapeutics; Graphite Bio; iTeos Therapeutics; Karuna Therapeutics; MBX Biosciences; MPM Capital; Nimbus Therapeutics; ProQR Therapeutics; PureTech Health; Relay Therapeutics; Rheos Medicines; Tango Therapeutics; TCR2 Therapeutics; Third Rock Ventures; Vericel Corporation and Versant Ventures.
Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.
Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.